evidence/gaps
Cochrane · systematic review · CD011661

Etrolizumab for induction of remission in ulcerative colitis

Rosenfeld, G, Parker, CE, MacDonald, JK, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library

GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Etrolizumab versus placebo for induction of remission in ulcerative colitis

Population: patients with induction of remission in ulcerative colitis
7 questions
OutcomeEffectEvidenceStatus / GRADE
Failure to enter clinical remission at week 10
Etrolizumab vs placebo
RR 0.86 [0.77, 0.95]1 study · 119 participantsModerate
Downgraded: imprecision
Failure to enter clinical remission at week 10 ‐ 100 mg
Etrolizumab vs placebo
RR 0.81 [0.68, 0.96]1 study · 59 participantsModerate
Downgraded: imprecision
Failure to respond at week 10
Etrolizumab vs placebo
RR 0.96 [0.75, 1.23]1 study · 119 participantsModerate
Downgraded: imprecision
Failure to enter endoscopic remission at week 6
Etrolizumab vs placebo
RR 0.98 [0.9, 1.06]1 study · 119 participantsModerate
Downgraded: imprecision
Failure to enter endoscopic remission at week 10
Etrolizumab vs placebo
RR 0.92 [0.85, 1]1 study · 119 participantsModerate
Downgraded: imprecision
Adverse events
Etrolizumab vs placebo
RR 0.75 [0.57, 0.99]1 study · 124 participantsModerate
Downgraded: imprecision
Serious adverse events
Etrolizumab vs placebo
RR 0.92 [0.36, 2.34]2 studies · 165 participantsLow
Downgraded: imprecision